Memphis Pharmaceuticals results, Q4 2022
Net profit, assets, equity and cash flow for Q4 2022, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit74.09 millionEGP
Total assets560 millionEGP
Shareholders' equity36.64 millionEGP
Operating cash flow36.47 millionEGP
In short
- Memphis Pharmaceuticals's net profit for Q4 2022 was about 74.09 million EGP.
- Total assets at the end of Q4 2022 were about 560 million EGP, and shareholders' equity about 36.64 million EGP.
- Operating cash flow for Q4 2022 was positive at 36.47 million EGP.
Key lines against the same period a year earlier
This periodYear earlierChange
Net profit74.09 million——
Gross profit157 million——
Total assets560 million——
Total liabilities524 million——
Shareholders' equity36.64 million——
Total liabilities and equity560 million——
Operating cash flow36.47 million——
Investing cash flow-3.38 million——
Financing cash flow———
Net change in cash31.23 million——
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Memphis Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy